Androgens exert effects on virtually all bodily tissues, and have a multitude of physiological roles in health. Testosterone, the predominant androgen in men, when deficient (hypogonadism), leads to a multiplicity of symptoms and signs that are corrected with physiological substitution. The impact of hypogonadism depends on the age at which it occurs. In any case, when testosterone replacement is initiated close monitoring for efficacy and safety is advised. The relation of ageing, the metabolic syndrome, type 2 diabetes, obesity and survival with plasma testosterone has been closely examined in recent studies. However, the effect of testosterone replacement therapy on the above clinical states needs to be clarified in large long-term duration/outcome studies. Recent research has shed light on possible molecular testosterone targets. Based on those research outcomes, drugs targeting the androgen receptor, which spare androgenic effects and preserve anabolic tissue effects, called selective androgen receptor modulators (SARMS), are under clinical trials. The role of testosterone in regulating erectile function has been studied in animal models and critical tissue testosterone targets have been elucidated.
BhasinS, CunninghamGR, HayesFJ, Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab2006;91:1995–2010
2.
SnyderPJ. Hypogonadism in elderly men – what to do until the evidence comes. N Engl J Med2004;350:440–2
3.
WrightAS, DouglasRC, ThomasLN, LazierCB, RittmasterRS. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinology1999;140:4509–15
4.
NarayananR, MohlerML, BohlCE, MillerDD, DaltonJT. Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal2008;6:e010. Epub 2008 Nov 26
BuenaF, SwerdloffRS, SteinerBS, Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil Steril1993;59:1118–23
7.
MoralesA, HeatonJP. Hypogonadism and erectile dysfunction: pathophysiological observations and therapeutic outcomes. BJU Int2003;92:896–9
TraishAM, GoldsteinI, KimNN. Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur Urol2007;52:54–70
RhodenEL, MorgentalerA. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med2004;350:482–92
12.
AraujoAB, EscheGR, KupelianV, Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab2007;92:4241–7
13.
WuFC, TajarA, PyeSR, Hypothalamic–pituitary–testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab2008;93:2737–45
14.
HarmanSM, MetterEJ, TobinJD, Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab2001;86:724–31
15.
FeldmanHA, LongcopeC, DerbyCA, Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab2002;87:589–98
16.
KaufmanJM, VermeulenA. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev2005;26:833–76
17.
NieschlagE, SwerdloffR, BehreHM, Investigation, treatment, and monitoring of late onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl2006;27:135–7
18.
MoralesA, SchulmanCC, TostainJ, WuCW. Testosterone deficiency syndrome (TDS) needs to be named appropriately – the importance of accurate terminology. Eur Urol2006;50:407–9
19.
WangC, NieschlagE, SwerdloffR, ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res2009;21:1–8
20.
LambertsSW, van den BeldAW, van der LelyAJ. The endocrinology of aging. Science1997;278:419–24
21.
VermeulenA, GoemaereS, KaufmanJM. Testosterone, body composition and aging. J Endocrinol Invest1999;22:110–6
22.
BremnerWJ, VitielloMV, PrinzPN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab1983;56:1278–81
23.
LuboshitzkyR, Shen-OrrZ, HererP. Middle-aged men secrete less testosterone at night than young healthy men. J Clin Endocrinol Metab2003;88:3160–6
24.
CalofOM, SinghAB, LeeML, Adverse events associated with testosterone replacement in middle aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci2005;60:1451–7
25.
LaaksonenDE, NiskanenL, PunnonenK, Sex hormones, inflammation and the metabolic syndrome: in middle aged men: a population based study. Eur J Endocrinol2003;149:601–8
26.
MullerM, GrobbeeDE, den TonkelaarI, Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab2005;90:2618–23
27.
MaggioM, LauretaniF, CedaGP, Association between hormones and metabolic syndrome in older Italian men. J Am Geriatr Soc2006;54:1832–8
28.
LaaksonenDE, NiskanenL, PunnonenK, Testosterone and sex hormone binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care2004;27:1036–41
29.
KupelianV, PageST, AraujoAB, Low sex hormone binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab2006;91:843–50
30.
SimonD, PreziosiP, Barrett-ConnorE, Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia1992;35:173–7
31.
Barrett-ConnorE. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med1992;117:807–11
32.
AnderssonB, MarinP, LissnerL, Testosterone concentrations in women and men with NIDDM. Diabetes Care1994;17:405–11
33.
KapoorD, AldredH, JonesTH, Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care2007;30:911–7
34.
DhindsaS, PrabhakarS, SethiM, Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab2004;89:5462–8
35.
StellatoRK, FeldmanHA, HamdyO, Testosterone, sex hormone binding globulin and the development of type 2 diabetes in middle aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care2000;23:490–4
36.
HaffnerSM, ShatenJ, SternMP, Low levels of sex hormone binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. Am J Epidemiol1996;143:889–97
37.
OhJY, Barrett-ConnorE, WedickNM, Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo Study. Diabetes Care2002;25:55–60
38.
SimonD, CharlesMA, LahlouN, Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone. Diabetes Care2001;24:2149–51
39.
MarinP, HolmangS, JonssonL, The effects of testosterone treatment on body composition and metabolism in middle aged obese men. Int J Obes Relat Metab Disord1992;16:991–7
40.
MalkinCJ, JonesTH, ChannerKS. The effect of testosterone on insulin sensitivity in men with heart failure. Eur J Heart Fail2006;9:44–50
41.
BoyanovMA, BonevaZ, ChristovVG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male2003;6:1–7
42.
KapoorD, GoodwinE, JonesTH, Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol2006;154:899–906
43.
KapoorD, JonesTH. Androgen deficiency as a predictor of metabolic syndrome in aging men. An opportunity for intervention?Drugs Aging2008;25:357–69
44.
PasqualiR, CasimirriF, CantobelliS, Effect of obesity and high body fat distribution on sex hormones and insulin in men. Metabolism1991;40:101–4
45.
ZumoffB, StrainGW, MillerLK, Plasma free non sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab1990;71:929–31
46.
HaffnerSM, ValdezRA, SternMP, Obesity, body fat distribution and sex hormones in men. Int J Obes1993;17:643–9
47.
SeidellJC, BjorntorpP, SjostromL, Visceral fat accumulation in men is positively associated with insulin, glucose and C-peptide levels but negatively with testosterone levels. Metabolism1990;39:897–901
48.
StrainGW, ZumoffB, MillerLK, Effect of massive loss on hypothalamic–pituitary–gonadal function in obese men. J Clin Endocrinol Metab1988;66:1019–23
49.
NiskanenL, LaaksonenDE, PunnonenK, Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab2004;6:208–15
50.
LaughlinGA, Barrett-ConnorE, BergstromJ. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab2008;93:68–75
51.
ShoresMM, MatsumotoAM, SloanKL, Low serum testosterone and mortality in male veterans. Arch Intern Med2006;166:1660–5
52.
AraujoAB, KupelianV, PageST, Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med2007;167:1252–60
53.
GreensteinA, MabjeeshNJ, SoferM, KaverI, MatzkinH, ChenJ. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed?J Urol2005;173:530–2
54.
ShabsighR, KaufmanJM, SteidleC, Padma-NathanH. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol2004;172:658–63
55.
RosenthalBD, MayNR, MetroMJ, HarkawayRC, GinsbergPC. Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology2006;67:571–4
